Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Weighted Average) (2016 - 2026)

Mimedx's Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $148.4 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 0.8% to $148.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $148.4 million, a 0.8% increase, with the full-year FY2025 number at $147.8 million, up 0.55% from a year prior.
  • Shares Outstanding (Weighted Average) hit $148.4 million in Q1 2026 for Mimedx, roughly flat from $147.8 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for MDXG hit a ceiling of $148.4 million in Q1 2026 and a floor of $111.6 million in Q1 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $131.8 million across 5 years, with a median of $146.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 27.98% in 2024 and later increased 0.49% in 2025.
  • Tracing MDXG's Shares Outstanding (Weighted Average) over 5 years: stood at $112.9 million in 2022, then grew by 3.18% to $116.5 million in 2023, then increased by 26.17% to $147.0 million in 2024, then increased by 0.55% to $147.8 million in 2025, then grew by 0.44% to $148.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MDXG at $148.4 million in Q1 2026, $147.8 million in Q4 2025, and $148.0 million in Q3 2025.